Follow Health Care Reform Insider on Twitter
You are here:  Home  >  Emerging Healthcare Models  >  Current Article

Harvard Pilgrim cements risk-based contract for pricey cholesterol drug Repatha

November 10, 2015 

Health insurer Harvard Pilgrim Health Care has struck a deal with drugmaker Amgen for its new cholesterol-lowering drug, Repatha.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>